Clinical Trials
8 trialsNCT03982134 2019-10-04
PDR001 + Panobinostat for Melanoma and NSCLC
University of Iowa
Phase 1 Withdrawn
NCT03632317 2019-08-19
A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT02802163 2017-04-25
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Withdrawn
NCT02961816 2017-04-21
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT00993642 2017-03-13
ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer
Tulane University
Phase EARLY_PHASE1 Withdrawn
NCT02756663 2016-11-08
PANORAMA-5
Novartis
Phase 2 Withdrawn
NCT01160731 2014-12-31
Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Cancer Trials Ireland
Phase 1 Withdrawn
NCT01115036 2013-06-19
CLBH589C
Duke University
Phase 2 Withdrawn